• Species Reactivity

  Human

• Specificity

  Detects human Complement Component C1s in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than    
  2% cross?reactivity with recombinant human C1r is observed.

• Source

  Polyclonal Sheep IgG

• Purification

  Antigen Affinity-purified

• Immunogen

  Mouse myeloma cell line NS0-derived recombinant human Complement Component C1s    
  Glu16-Asp688    
  Accession # P09871

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS.

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• Western Blot

  0.1 μg/mL

  Recombinant Human Complement Component C1s (Catalog # )

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Preparation and Storage

• Reconstitution

  Reconstitute at 0.2 mg/mL in sterile PBS.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Complement Component C1s

The classical complement pathway plays a major role in innate immunity against infection. This pathway is triggered by C1, a multimolecular complex composed of the recognition protein C1q and two serine proteases, C1r and C1s. Following the C1q recognition, C1r is autoactivated, and in turn activates C1s, which cleaves C4 and C2, the C1 substrates (1). Both C1r and C1s activation involve cleavage of a specific Arg-Ile bond, converting single-chain proenzymes into active proteases of disulfide bond-linked chains (A and B) (2). The A chains contain multiple domains in the order of CUB1-EGF-CUB2-CCP1-CCP2-Activation Peptide. The B chains contain the serine protease catalytic domain. The full-length (amino acid residues 1?688) of human C1s was expressed (3?5). The purified protein corresponded to the processed active form, with A and B chains starting at residue Glu16 and Ile438, respectively.

• References:

1. Arlaud, G.J. et al. (2002) Biochem. Soc. Trans. 30:1001.

2. Lacroix, M. et al. (2001) J. Biol. Chem. 276:36233.

3. Tosi, M. et al. (1987) Biochemistry 26:8516.

4. Mackinnon, C.M. et al. (1987) Eur. J. Biochem. 169:547.

5. Kusumoto, H. et al. (1988) Proc. Natl. Acad. Sci. USA 85:7307.

• Entrez Gene IDs:

  716 (Human)

• Alternate Names:

  basic proline-rich peptide IB-1; C1 esterase; C1S; complement C1s subcomponent; Complement component 1 subcomponent s; complement component 1, s subcomponent; Complement Component C1s; EC 3.4.21; EC 3.4.21.42; FLJ44757